Table 3.
Study Characteristics for Trials Comparing Antidepressants and Placebo in Adults with Chronic Insomnia
| First Author/Year | Sample Size, n, enrolled | Mean Age ± SD or (Range), in years | Number of Females/Males or (Percentage Female/Male) | Psychiatric Illness | Quality Score (Jadad) | Intervention | ||
|---|---|---|---|---|---|---|---|---|
| Drug | Dose, mg | Duration | ||||||
| Haffmans PMJ/1999* | 7 | 44 ± NS (NS) | 3/4 | Previous severe major depression | 4 | Trazodone | 150–250 | 7 nights |
| Hajak G/1996* | 15 | 41.3 ± 9.5 | 3/7 | NS | 3 | Doxepin | 25 | 5 weeks |
| Hajak G/2001 | 47 | Doxepin: 47.6 ± 11.3, PL: 47.4 ± 16.8 | 36/11 | NS | 3 | Doxepin | 25–50 | 4 weeks |
| Hornyak M/2005 | 40 | TR: 45.3 ± 13, PL: 51.3 ± 9.4 | NS | NS | 2 | Doxepin | 25 to 50 | 4 weeks |
| Negri L/1997* | 100 | 42.95 ± 13.22 | 70/30 | Anxiety alone and mild depressive symptoms | 2 | Pivagabine | 900 | 30 days |
| Riemann D/2002 | 65 | Lormetazepam: 45.3 ± 10.3, trimipramine: 47.0 ± 10.8, PL: 48.8 ± 11.6 | 23/32 | NS | 3 | lormetazepam; trimipramine | 1;25–200 | 28 days |
| Rodenbeck A/2003* | 10 | 41.3 ± 9.5 | 3/7 | NS | 3 | Doxepin | 25 | 1 night |
| Walsh JK/1998 | 589 | 42 ± NS (21–65) | 193/85 | NS | 3 | Zolpidem; trazodone | 10, 50 | 14 nights |